Juli Miller | Head-Investor Relations |
Adrian Rawcliffe | Chief Executive Officer |
Elliot Norry | Chief Medical Officer |
Gavin Wood | Chief Financial Officer |
Dennis Williams | Senior Vice President, Late Stage Development |
Jo Brewer | Chief Scientific Officer |
Helen Tayton-Martin | Chief Business and Strategy Officer |
Marc Frahm | Cowen & Company |
Tony Butler | Roth Capital Partners |
Mara Goldstein | Mizuho |
Jonathan Chang | SVP Securities |
Peter Lawson | Barclays |
Soumit Roy | Jones Trading |
Hello and welcome to Adaptimmune’s Third Quarter Call and Business Update. I would now turn the call over to Juli Miller. Juli, please go ahead.
Good morning and welcome to Adaptimmune’s conference call to discuss our third quarter 2022 financial results and business update. I would ask you to review the full text of our forward-looking statement from this morning’s press releases.